Prosecution Insights
Last updated: November 04, 2026
Application No. 18/607,998

BLENDED NANOPARTICLE FERTILIZER DELIVERY

Non-Final OA §112
Filed
Mar 18, 2024
Priority
Apr 12, 2019 — provisional 62/833,329 +1 more
Examiner
SMITH, JENNIFER A
Art Unit
1731
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Aqua Yield Operations LLC
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
6m
Est. Remaining
88%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allowance Rate
541 granted / 890 resolved
-4.2% vs TC avg
Strong +27% interview lift
Without
With
+27.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
40 currently pending
Career history
936
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
48.6%
+8.6% vs TC avg
§102
20.3%
-19.7% vs TC avg
§112
26.4%
-13.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 890 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application, which discloses and claims only subject matter disclosed in prior Application No. 16/844,881, filed 04/09/2020, appears to claim only subject matter directed to an invention that is independent and distinct from that claimed in the prior application, and names the inventor or at least one joint inventor named in the prior application. Accordingly, this application constitutes a divisional application. Information Disclosure Statement The information disclosure statement (IDS) submitted on 03/18/2024 has been considered by the examiner. Claim Objections Claims 1-5 are objected to because of the following informalities: Claim 1 is not drafted using typical “preamble” and “transitional phrase” syntax. Because the claims do not have a transition phrase formally denoting a preamble, it is not known if the claim terms are intended in the preambles of their respective claims. In Acceleration Bay, LLC v. Activision Blizzard Inc., the Federal Circuit cautioned patentees to avoid such “poor claim drafting” by including a transition word to clearly delineate between the preamble and the body. Claims 2-3 do not use standard active gerund/infinitive clause formatting for method steps following the main preamble. The claims lack proper transitional phrasing (e.g. wherein) and contain redundant verbiage. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 5 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 5 recites the limitation "nanoparticle supplement" in line 2. There is insufficient antecedent basis for this limitation in the claim. Allowable Subject Matter The claims would be allowable if rewritten or amended to overcome the objection(s) and rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. The prior art of record [Tomalia et al., Cite No. 1 in 03/18/2024 IDS] teaches the use of PAMAM dendrimers having a nanosize [Table I] as a means to deliver a payload like salicylic acid (e.g. PAMAM dendrimer formulations included a ratio of one salicylic acid (plant hormone) molecule bound (ready to deliver) to one terminal amine functional group in the polymer [column 42 lines 48-58]. However, the ratio of PAMAM to fertilizer is much larger than 6 ppm (e.g. 10 mg of salicylic acid and 25 mg of PAMAM are added to 10 ml of liquid solution (much greater than 10 ppm) [column 43 lines 5-9]. McLaughlin et al. [Cite No. 4 in 03/18/2024 IDS] teaches the use of PAMAM dendrimers to deliver micronutrients to plants (e.g. fertilizer composition increases rate of micronutrient uptake; composition includes a chelating polymer; the chelating polymer can be polyamidoamine and dendrimers thereof) [paragraphs (0027) and (0029)]; However, in the context of PAMAM, the relative amounts of nutrients and polymer are not discussed. The prior art references do not teach or render obvious all the cumulative limitations of independent claim 1 with particular attention to a fluid fertilizer mixture including fertilizer and a liquid medium having a volume ratio between 1 : 160 and 1 :32,000, adding dendrimer and spherical nanoparticles and applying the mixture to a plant. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure: Nilwala et al. (US 20110296885 A1) discloses a plant fertilizer and a process for the preparation of a nanocomposite that contains nitrogen containing macronutrient compounds [0006] Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer A Smith whose telephone number is (571)270-3599. The examiner can normally be reached Monday - Friday 9:30am-6pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amber R Orlando can be reached at (571) 270-3149. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JENNIFER A SMITH/Primary Patent Examiner, Art Unit 1731 October 21, 2026
Read full office action

Prosecution Timeline

Mar 18, 2024
Application Filed
Oct 23, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12758943
ENGINEERED CALCIUM ALGINATE AND USES THEREOF
4y 1m to grant Granted Oct 13, 2026
Patent 12753128
NITROGEN FERTILIZER COMPOSITIONS BASED ON POLYPHOSPHATE CAGED STRUCTURE
3y 5m to grant Granted Oct 06, 2026
Patent 12735367
ENCAPSULATED FERTILIZER COMPRISING ESSENTIAL OILS, POLYMERS AND MACRONUTRIENTS AND METHOD OF PREPARATION THEREOF
3y 3m to grant Granted Sep 15, 2026
Patent 12686649
METHOD FOR THE MANUFACTURE OF A UREA-BASED COMPOSITION COMPRISING THE ADDITION OF A LIQUID-FREE SOLID ADDITIVE
3y 1m to grant Granted Jul 21, 2026
Patent 12686648
METHOD FOR THE MANUFACTURE OF A UREA-BASED COMPOSITION COMPRISING THE ADDITION OF AN ADDITIVE IN AN AQUEOUS FORM
3y 1m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
88%
With Interview (+27.0%)
3y 1m (~6m remaining)
Median Time to Grant
Low
PTA Risk
Based on 890 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month